Business description
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Management board & Supervisory board
| CEO |
| Naoki Okamura |
| Management board |
| Atsushi Kitamura, Katsuyoshi Sugita, Yoshitsugu Shitaka, Tadaaki Taniguchi, Hideki Shima, Claus Zieler, Adam Pearson, Catherine Levitt, Nick Eshkenazi |
| Supervisory board |
| Kenji Yasukawa, Naoki Okamura, Katsuyoshi Sugita, Takashi Tanaka, Eriko Sakurai, Masahiro Miyazaki, Yoichi Ohno, Raita Takahashi, Mika Nakayama, Rie Akiyama, Tomoko Aramaki |
Company data
| Name: |
Astellas Pharma Inc. |
| Address: |
2-5-1, Nihonbashi-Honcho,Chuo-Ku, Tokyo 103-8411 |
| Phone: |
+81-3-3244-3000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.astellas.com/en/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
- |
| End of financial year: |
3/31 |
| Free Float: |
- |
| IPO date: |
- |
Investor relations
| Name: |
- |
| IR phone: |
+81-3-3244-3202 |
| IR Fax: |
- |
| IR e-mail: |
-
|
